Actovegin use in patients with cognitive impairment after coronavirus infection (COVID-19)

Abstract

Objective: to investigate the effectiveness of long-term oral administration of Actovegin in post-COVID patients with cognitive impairment (CI). Patients and methods. 444 patients (142 men, 302 women) with COVID-19 and CI participated in the study. One-half of the included participants - 222 patients (70 men and 152 women) - were prescribed with actovegin 400 mg 3 times a day in addition to the baseline therapy; 222 patients (72 men and 150 women) were randomized to the control group. Cognitive functions were assessed with Montreal Cognitive Assessment (Montreal Cognitive Assessment test, МоСA test), fatigue - with Multidimensional Fatigue Inventory (MFI-20), emotional disturbances - with Spielberger-Hanin test. Results and discussion. Post-COVID patients with CI in the Actovegin group after 60 days follow-up had higher mean MoCА scores (p<0.05), lower MFI (p<0.05), and Spielberger-Hanin test scores (p<0.05) compared to the control group. Conclusion. Positive effect of Actovegin on the cognitive functions and emotional state of post-COVID patients with CI was observed.